What is the latest market price of one dose of gerfitomab?

Glofitumab is an innovative bispecific antibody primarily used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma) and large B-cell lymphoma (LBCL) caused by follicular lymphoma. By simultaneously targeting CD20 and CD3, the drug achieves effective combination of tumor cells and T cells, thereby activating the inhibitory effect of T cells on tumor cells. This mechanism gives gaffetuzumab a unique advantage in anti-tumor therapy, especially for patients who have undergone multiple systemic therapies.

In terms of clinical application, gaffetuzumab is mainly targeted at adult patients whose disease is often uncontrolled after two or more systemic therapies. For such patients, gaffetuzumab provides a new treatment option, and its efficacy in clinical trials has shown good response rates, with some patients even achieving complete remission. Due to its unique bispecific design, gratinumab can effectively mobilize the body's immune system and enhance its ability to recognize and eliminate cancer cells, which brings new hope to patients.

Regarding price, grefitomab is currently on the Chinese market, but it has not yet been included in medical insurance, resulting in a relatively high price. Under normal circumstances, the price of each box of 10mg/10ml is about 30,000 yuan. In the international market, especially in Europe, the price of the original drug of Gefituzumab reaches more than 40,000 yuan per box. This price level puts many patients under financial pressure when undergoing treatment, especially if it is not covered by medical insurance.

It is worth noting that there are currently no generic drugs of greffitumab on the market, which makes market competition relatively limited, and patients’ access to the drug mainly relies on the original drug.

Reference materials:https://www.drugs.com/glofitamab.html